BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35741755)

  • 1. The Value of the Stemness Index in Ovarian Cancer Prognosis.
    Yuan H; Yu Q; Pang J; Chen Y; Sheng M; Tang W
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
    Lai J; Lin X; Zheng H; Xie B; Fu D
    BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Stemness Characteristics Associated With the Immune Microenvironment and Prognosis in Gastric Cancer.
    Mao D; Zhou Z; Song S; Li D; He Y; Wei Z; Zhang C
    Front Oncol; 2021; 11():626961. PubMed ID: 33747944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
    Fei H; Han X; Wang Y; Li S
    J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
    Zheng P; Li N; Zhan X
    Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
    Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
    J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
    Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
    Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
    Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
    Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
    [No Abstract]   [Full Text] [Related]  

  • 10. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
    Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
    Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
    Xu Q; Xu H; Chen S; Huang W
    Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer.
    Wang Y; Li BX; Li X
    Front Oncol; 2021; 11():783666. PubMed ID: 35047401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
    Guo Y; Li S; Li C; Wang L; Ning W
    Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the role of tumor stemness and the potential of stemness-related risk model in the prognosis of intrahepatic cholangiocarcinoma.
    Yue Y; Tao J; An D; Shi L
    Front Genet; 2022; 13():1089405. PubMed ID: 36712866
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
    Zhu K; Ma J; Tian Y; Liu Q; Zhang J
    BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Cancer Stemness-Related Signature for Predicting Prognosis in Patients with Colon Adenocarcinoma.
    Wang W; Xu C; Ren Y; Wang S; Liao C; Fu X; Hu H
    Stem Cells Int; 2021; 2021():7036059. PubMed ID: 34691191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
    Liu J; Liu Y; Yang C; Liu J; Hao J
    Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.